Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 09, 2024 08:00 ET | Source: Disc Medicine Inc

Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update

Presented top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), in April 2024On track to deliver additional analyses from BEACON and...
April 01, 2024 08:00 ET | Source: Disc Medicine Inc

Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)

Met primary endpoint, demonstrating dose-dependent, statistically significant reductions in protoporphyrin IX (PPIX) compared to placebo in both 20 mg and 60 mg dose groupsImproved measures of light...
March 21, 2024 08:00 ET | Source: Disc Medicine Inc

Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), expected March / April 2024On track to deliver multiple read-outs in 2024,...
March 06, 2024 16:30 ET | Source: Disc Medicine Inc

Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024

WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
February 26, 2024 08:30 ET | Source: Disc Medicine Inc

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer

WATERTOWN, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
February 20, 2024 08:30 ET | Source: Disc Medicine Inc

Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

WATERTOWN, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
February 09, 2024 09:00 ET | Source: Disc Medicine Inc

Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera

WATERTOWN, Mass., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
February 07, 2024 08:00 ET | Source: Disc Medicine Inc

Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer

Jean Franchi is an industry veteran and brings over 30 years of leadership experience in finance, investor relations, capital formation, and operations at both development and commercial-stage...
January 03, 2024 17:00 ET | Source: Disc Medicine Inc

Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
December 20, 2023 16:30 ET | Source: Disc Medicine Inc

Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board

WATERTOWN, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON) (“Disc”), a clinical-stage biopharmaceutical company focused on the discovery, development, and...